Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

摘要

Programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors are a significant advance in the treatment of patients with nonesmall-cell lung cancer. In this study we investigated the comparative safety and efficacy of these agents when used in patients who are chemotherapy-naive vs. patients previously treated with chemotherapy.